|
| 1 |
Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
Justin M. Hintze, Holly Jones, Peter Lacy
J Rhinol.2023;30(2):125-128. Published online 2023 July 28
DOI: http://dx.doi.org/10.18787/jr.2023.00022
|
|
| 2 |
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non–Small Cell Lung Cancer
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat.2022;54(4):1005-1016. Published online 2021 December 3
DOI: http://dx.doi.org/10.4143/crt.2021.986
|
|
| 3 |
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Jwa Hoon Kim, Bokyung Ahn, Seung-Mo Hong, Hwoon-Yong Jung, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Jeong Hoon Lee, Hee Kyoung Na, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Sung-Bae Kim, Sook Ryun Park
|
|
| 4 |
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Dong Won Baek, Yee Soo Chae
|
|
| 5 |
Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
Joon Young Hur, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Blood Res.2020;55(2):85-90. Published online 2020 June 30
DOI: http://dx.doi.org/10.5045/br.2020.2020014
|
|
| 6 |
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Res Treat.2020;52(2):594-603. Published online 2019 December 18
DOI: http://dx.doi.org/10.4143/crt.2019.493
|
|
| 7 |
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
Ye Jin Lee, Hak Tae Kim, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Woo Jin Lee
|
|
| 8 |
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kim
Cancer Res Treat.2019;51(2):611-622. Published online 2018 July 20
DOI: http://dx.doi.org/10.4143/crt.2018.191
|
|
| 9 |
Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review
Myeong Seon Kim, Chel-Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Jeeyun Lee, Duk-Soo Bae, Byoung-Gie Kim
|
|
| 10 |
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
Haa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Lee
Cancer Res Treat.2018;50(4):1458-1461. Published online 2018 January 22
DOI: http://dx.doi.org/10.4143/crt.2017.529
|
|
